Literature DB >> 7454207

Simultaneous correction of blepharoptosis and exotropia in aberrant regeneration of the oculomotor nerve by strabismus surgery: a new, simplified ptosis correction for selected cases.

F E O'Donnell, M Del Monte, D L Guyton.   

Abstract

Selected patients with blepharoptosis and exotropia with aberrant regeneration of the oculomotor nerve can achieve acceptable cosmesis by simple strabismus surgery. Patients with good lid position on attempted contralateral gaze are candidates for this new approach. With aberrant regeneration of the oculomotor nerve, the affected levator frequently becomes pathologically yoked to the contralateral lateral rectus muscle. In these cases, the ecotropia is corrected by a recess-resect procedure primarily or exclusively on the contralateral fixing eye such that postoperatively. The fixing eye is "abducted" by the patient to the primary position, and the ptotic lid elevates simultaneously.

Entities:  

Mesh:

Year:  1980        PMID: 7454207

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  5 in total

1.  Results following treatment of third cranial nerve palsy in children.

Authors:  L A Schumacher-Feero; K W Yoo; F M Solari; A W Biglan
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Treatment of ocular motor palsies.

Authors:  Imran Jivraj; Vivek Patel
Journal:  Curr Treat Options Neurol       Date:  2015-03       Impact factor: 3.598

3.  Surgical management of third nerve palsy.

Authors:  C P Noonan; M O'Connor
Journal:  Br J Ophthalmol       Date:  1995-05       Impact factor: 4.638

4.  Contralateral eye surgery with adjustable suture for management of third nerve palsy with aberrant regeneration.

Authors:  Phuong Thi Thanh Nguyen; Shailja Tibrewal; Suma Ganesh
Journal:  Indian J Ophthalmol       Date:  2017-10       Impact factor: 1.848

5.  Surgical strategy for third nerve palsy with aberrant regeneration: Harnessing the aberrant power.

Authors:  Shweta Chaurasia; Pradeep Sharma; Pranav Kishore; Abhijit Rasal
Journal:  Indian J Ophthalmol       Date:  2021-04       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.